Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106633 · ClinicalTrials.gov registry record · NA
Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT06106633: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT06106633 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106633, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this study is to assess of Pressure-Enabled Drug Delivery on fibroid treatment in patients undergoing UFE.
Interventions
- DEVICE TriNaV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-02-09 |
| Est. Completion | 2025-01-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106633
The ClinicalTrials.gov registry entry for NCT06106633 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TriNaV is the first listed.
NCT06106633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06106633 about?
NCT06106633 is a clinical study titled "Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization". The goal of this study is to assess of Pressure-Enabled Drug Delivery on fibroid treatment in patients undergoing UFE.
What is the current status of trial NCT06106633?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2023-02-09. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT06106633?
The interventions under investigation include: TriNaV (DEVICE).
Who is sponsoring clinical trial NCT06106633?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.